Patents Assigned to Washington, University of
-
Publication number: 20240150764Abstract: The present disclosure provides for splice-switching oligonucleotides (SSOs) targeted to a nucleic acid encoding a transposable element (TE)-driven isoform of LIN28B, such as AluJb-LIN28B. The SSOs may be targeted to an exon-intron or intron-exon junction to inhibit splicing and expression of the TE-driven isoform of LIN28B. Methods of treating cancer, particularly cancers expressing AluJb-LIN28B, comprising administering the SSOs are also provided.Type: ApplicationFiled: November 7, 2023Publication date: May 9, 2024Applicant: Washington UniversityInventors: Noah Basri, Ting Wang
-
Patent number: 11975970Abstract: High quality carbon nanochains or carbon nanotubes are produced by methods that include mixing a carbon-containing feedstock with a catalyst to form a feedstock/catalyst mixture, or coating a catalyst with a carbon-containing feedstock, and subjecting the feedstock/catalyst mixture or feedstock-coated catalyst to irradiation with a laser to convert the feedstock into carbon nanochains or carbon nanotubes in the presence of the catalyst. In some instances, the feedstock is converted to a char by pyrolysis and the char is instead subjected to laser irradiation. The carbon-containing feedstock can be a biomass or a carbonaceous material. In some instances, the catalyst is a metal salt, preferably a transition metal salt. In some instances, the catalyst is an elemental metal, an alloy, or a combination thereof.Type: GrantFiled: July 23, 2021Date of Patent: May 7, 2024Assignee: The George Washington UniversityInventors: Michael J. Wagner, Nathan A. Banek, Dustin T Abele, Kevin R. McKenzie, Jr.
-
Publication number: 20240138838Abstract: An anastomosis device for joining a first and second end of a vascular vessel is disclosed that includes a polymer cylinder ending in opposed first and second vascular-retaining ends configured for insertion into the first and second ends of the vascular vessel respectively. Each vascular-retaining end includes a plurality of bristles protruding outward. The device also includes at least one moiety covalently coupled to the surface of the device. The at least one moiety is selected from at least one anti-coagulant, at least one cell-specific binding peptide, and any combination thereof.Type: ApplicationFiled: May 15, 2023Publication date: May 2, 2024Applicant: Washington UniversityInventors: Xiaowei Li, Justin Sacks, William Moritz, Emran Madatov, Mohamed Zayed
-
Patent number: 11964001Abstract: The present invention provides compositions and method for treating a subject having or suspected of having pulmonary dysfunction resulting from impaired alveolar macrophage (AM) development. The compositions comprise granulocyte-macrophage colony stimulating factor (GM-CSF) in formulations suitable for pulmonary airway administration.Type: GrantFiled: April 9, 2020Date of Patent: April 23, 2024Assignee: Washington UniversityInventors: Sharon Celeste Morley, Elizabeth M. Todd
-
Publication number: 20240122631Abstract: A screw locating system including an intramedullary nail, a locating hole at the distal end of the intramedullary nail, a locator pin including a hollow section, and a locating end configured to fit in the locating hole, a cap configured to fill in the locating hole when the locator pin is in the locating hole, a screw configured to securely hold the locator pin, and a jig configured to guide a user to locate at least one distal screw at the distal end of the intramedullary nail.Type: ApplicationFiled: October 14, 2022Publication date: April 18, 2024Applicant: WESTERN WASHINGTON UNIVERSITYInventors: Sura Al-Qudah, Ala' K. Al-Qudah, Levi Smith
-
Publication number: 20240124610Abstract: The present disclosure provides methods for treating a subject having a HER2 non-amplified (HER2-negative) cancer or low HER2 expressing (HER2-low) cancer, comprising detecting expression of a BCAR4 gene fusion in a biological sample from the subject. If expression of the BCAR4 gene fusion is detected, a HER2-targeted cancer treatment is administered to the subject; if expression of the BCAR4 gene fusion is not detected, a cancer treatment that is not HER2-targeted is administered to the subject. Methods of predicting response to a HER2-targeted cancer treatment and detecting BCAR4 or BCAR4 gene fusion activation are also provided.Type: ApplicationFiled: May 16, 2023Publication date: April 18, 2024Applicant: Washington UniversityInventors: Nicole Maher, Christopher Maher, Andrew Nickless, Jin Zhang, Amy Ly, Jace Webster
-
Publication number: 20240124553Abstract: The present disclosure is directed to compositions and methods of treating arthritogenic alphavirus infection. Compositions include a fusion protein comprising an Fc region, a first Mxra8 region, and a second Mxra8 region, wherein the fusion protein reduces inflammation and infection by an arthritogenic alphavirus. Methods include administering the fusion protein to a mammalian or non-mammalian subject to reduce or inhibit alphavirus infection.Type: ApplicationFiled: September 22, 2023Publication date: April 18, 2024Applicant: Washington UniversityInventors: Michael Diamond, Daved Fremont, Rong Zhang, Arthur Kim, Larissa Thackray, Katherine Basore, Christopher A. Nelson, Ofer Zimmerman, Maxwell Zimmerman, Saravanan Raju
-
Publication number: 20240115675Abstract: The present disclosure relates to methods of treating a tumor with a nucleotide vaccine (e.g., DNA vaccine encoding a tumor antigen) in combination with an IL-7. In some aspects, the IL-7 is administered after the administration of the nucleotide vaccine (e.g., after the peak expansion phase of the tumor-specific T cell immune response) or concurrently with the nucleotide vaccine.Type: ApplicationFiled: November 5, 2021Publication date: April 11, 2024Applicants: NeoImmuneTech, Inc., Washington UniversityInventors: Byung Ha LEE, Donghoon CHOI, William GILLANDERS, Ina CHEN, Simon Peter GOEDEGEBUURE, Lijin LI
-
Patent number: 11952410Abstract: The present disclosure provides constructs that comprise (a) a TNF-related apoptosis-inducing ligand (TRAIL) trimer comprising three consecutive extracellular TRAIL domains fused together in a head-to-tail configuration; (b) an epitope binding agent, and (c) optionally one or more additional components, wherein the epitope binding agent competitively inhibits binding of P4-TR3 or HN1-TR3 to cell surface human mesothelin. Constructs of the present disclosure induce apoptosis in cells expressing human mesothelin and a death receptor (DR4 or DR5) on the cell's surface.Type: GrantFiled: May 2, 2018Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Dirk M. Spitzer, William G. Hawkins
-
Patent number: 11952417Abstract: The present invention is directed towards isolated antibodies that bind to IL12R?1. Specifically, anti-IL12R?1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.Type: GrantFiled: December 9, 2021Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Marco Colonna, Cristiane Secca da Silva
-
Publication number: 20240108625Abstract: The present disclosure provides for compositions and methods of use of CDK4/6 inhibitors to prevent therapy-related clonal hematopoiesis and associated myeloid neoplasms.Type: ApplicationFiled: October 3, 2023Publication date: April 4, 2024Applicant: Washington UniversityInventor: Kelly Bolton
-
Patent number: 11949136Abstract: Described herein are direct liquid fuel cells with an alkaline anodic fuel stream including a solution of liquid fuel such as alcohols, ethers, glycols or compounds of hydrazine, and an acidic cathode oxidant stream including a solution of a suitable oxidant such as hydrogen peroxide or a gas steam with 1% to 100% O2. These cells are used as primary stationary and/or mobile power sources and also function in a secondary role as range extenders when coupled with a primary power source.Type: GrantFiled: October 27, 2020Date of Patent: April 2, 2024Assignee: Washington UniversityInventors: Zhongyang Wang, Vijay K. Ramani, Shrihari Sankarasubramanian
-
Patent number: 11944964Abstract: A micro-bioelectrochemical cell (?-BEC) device is disclosed that includes from 4 to 96 microfluidically connected of chambers, in which each chamber encloses a volume of about 1 ?L to 2 ?L. A working electrode, reference electrode, and counting electrode contacts each volume. The ?-BEC device includes a support layer coated with a working electrode layer, a microfluidics layer containing a plurality of wells, and an electrical layer containing the reference and counter electrodes. Methods of using the ?-BEC device to perform bioelectrochemical measurements of cells are also disclosed.Type: GrantFiled: January 29, 2020Date of Patent: April 2, 2024Assignee: Washington UniversityInventors: John Mark Meacham, Arpita Bose, Michael M. Binkley
-
Patent number: 11944768Abstract: A method of using a catheter assembly for inserting in a fluid filled space in a body includes providing a main body having a first end portion and a second end portion. The first end portion is positioned within the fluid filled space. The second end portion is adjusted to extend outwardly from the fluid filled space when the first end portion is positioned within the fluid filled space. A catheter tip is connected to the second end portion of the main body. The catheter tip includes a housing having a cavity defined therein and a rotating element positioned within the fluid filled space. The rotating element is rotated within the cavity of the housing to impart movement of the first end portion of the main body within the fluid filled space.Type: GrantFiled: August 17, 2020Date of Patent: April 2, 2024Assignee: Washington UniversityInventors: Eric Leuthardt, Guy Genin, Matthew Smyth, David Limbrick, Daniel Moran, Lihong Wang, Aaron McLaughlin, Manish Shah, Alexander Yang, Samuel Stone, Devon Haydon, Michael Winek, Richard Marcus
-
Publication number: 20240102102Abstract: Among the various aspects of the present disclosure is the provision of treatments, monitoring treatment or progression, or methods for detecting utDNA in a subject having or suspected of having a urinary tract-associated cancer.Type: ApplicationFiled: January 18, 2022Publication date: March 28, 2024Applicant: Washington UniversityInventors: Aadel Chaudhuri, Kevin Chen, Pradeep Chauhan, Zachary Smith, Vivek Arora
-
Patent number: 11938138Abstract: Among the various aspects of the present disclosure is the provision of a methods for increasing chemotherapy sensitivity or decreasing chemotherapy resistance using BET inhibitors.Type: GrantFiled: July 9, 2021Date of Patent: March 26, 2024Assignee: Washington UniversityInventors: Robi Mitra, Arnav Moudgil, Michael Nathaniel Wilkinson
-
Patent number: 11938193Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.Type: GrantFiled: January 9, 2017Date of Patent: March 26, 2024Assignee: Washington UniversityInventors: Russell Pachynski, Holbrook Kohrt, Jason Yonehiro, Brian Zabel
-
Patent number: 11933791Abstract: Provided herein are methods for determining the severity of glaucoma using expression levels of GDF15. Determining the severity of glaucoma can aid in making treatment decisions.Type: GrantFiled: August 25, 2021Date of Patent: March 19, 2024Assignee: Washington UniversityInventors: Rajendra S. Apte, Jun Yoshino
-
Patent number: 11931366Abstract: The present disclosure relates generally compositions and methods of using the same for the treatment of proteinopathies (e.g. Alpha-1-antitrypsin deficiency, Non-alcoholic fatty liver disease, Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease) with one or more proteotoxicity reducing agents.Type: GrantFiled: April 19, 2019Date of Patent: March 19, 2024Assignee: Washington UniversityInventors: Stephen Pak, David Perlmutter, Gary Silverman
-
Patent number: 11931412Abstract: The present invention provides methods for treating pruritus having a neurogenic component in a subject in need thereof comprising administering a therapeutically effective amount of a JAK1 inhibitor based on a benzimidazole core, a purine core, or a pyrrolo pyridine core.Type: GrantFiled: February 4, 2021Date of Patent: March 19, 2024Assignee: Washington UniversityInventor: Brian Kim